Jeffrey N Miner Selected Research

lesinurad

1/2019	Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
10/2016	Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
10/2016	Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
6/2016	Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
12/2014	Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey N Miner Research Topics

Disease

22	Gout 01/2020 - 12/2014
7	Neoplasms (Cancer) 01/2016 - 07/2005
5	Hyperuricemia 01/2018 - 10/2016
3	Inflammation (Inflammations) 01/2018 - 05/2008
2	Pain (Aches) 01/2018 - 01/2016
2	Melanoma (Melanoma, Malignant) 03/2013 - 09/2009
1	Body Weight (Weight, Body) 01/2018
1	Renal Insufficiency (Renal Failure) 06/2016
1	Headache (Headaches) 06/2016
1	Nasopharyngitis 06/2016
1	Arthralgia (Joint Pain) 06/2016
1	Anaphylaxis (Anaphylactic Shock) 01/2016
1	Gouty Arthritis 01/2016
1	Ascites 10/2013
1	Hepatocellular Carcinoma (Hepatoma) 10/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2010
1	Carcinoma (Carcinomatosis) 09/2009
1	Breast Neoplasms (Breast Cancer) 03/2008
1	Multiple Myeloma 09/2007
1	Frailty 01/2007
1	Osteoporosis 01/2007
1	Cushing Syndrome 01/2003

Drug/Important Bio-Agent (IBA)

19	Uric Acid (Urate)IBA 01/2020 - 12/2014
6	verinuradIBA 01/2018 - 01/2017
5	lesinuradIBA 01/2019 - 12/2014
5	Allopurinol (Remid)FDA LinkGeneric 12/2018 - 06/2016
4	N- (3,4- difluoro- 2- (2- fluoro- 4- iodophenylamino)- 6- methoxyphenyl)- 1- (2,3- dihydroxypropyl)cyclopropane- 1- sulfonamideIBA 01/2016 - 09/2009
3	Colchicine FDA LinkGeneric 01/2018 - 12/2014
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2016 - 09/2010
2	CreatinineIBA 01/2020 - 06/2016
2	Febuxostat FDA Link 01/2018 - 12/2014
2	Pharmaceutical PreparationsIBA 10/2016 - 09/2010
2	Urate Oxidase (Uricase)IBA 01/2016 - 01/2016
2	Sorafenib (BAY 43-9006)FDA Link 01/2016 - 10/2013
2	GlucocorticoidsIBA 05/2008 - 01/2003
2	AndrogensIBA 03/2008 - 01/2007
1	Oxypurinol (Oxipurinol)IBA 12/2018
1	IronIBA 01/2018
1	AcidsIBA 01/2018
1	Ferritins (Ferritin)IBA 01/2018
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2018
1	BenzbromaroneIBA 10/2016
1	urate transporterIBA 10/2016
1	Probenecid (Benemid)FDA LinkGeneric 10/2016
1	Xanthine OxidaseIBA 12/2014
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2013
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2013
1	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 03/2013
1	Sirolimus (Rapamycin)FDA Link 09/2010
1	Androgen Receptors (Androgen Receptor)IBA 03/2008
1	Actins (F Actin)IBA 03/2008
1	Dexamethasone (Maxidex)FDA LinkGeneric 09/2007
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 09/2007
1	Hormones (Hormone)IBA 07/2005
1	LigandsIBA 07/2005
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2003

Therapy/Procedure

5	Therapeutics 01/2017 - 03/2013
1	Intra-Articular Injections 01/2018
1	Punctures 01/2018
1	Aftercare (After-Treatment) 03/2017